Business Context and Reporting Period
This Form 8-K Current Report is filed by TriSalus Life Sciences, Inc. (TLSI) for the reporting period ending September 30, 2025. The company is incorporated in Delaware and trades on the Nasdaq Global Market under the symbols TLSI (Common Stock) and TLSIW (Warrants). The registrant is classified as an emerging growth company.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the departure of a director:
- Sean Murphy resigned from his position as a member of the Board of Directors and the Science and Technology Committee, effective immediately on September 30, 2025.
- The Company states that Mr. Murphy's resignation is not the result of any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on financial performance, specific risks, contingencies, or unusual items beyond the director resignation.
Key Facts for Investor Verification
- Verify the impact of Sean Murphy's departure on the composition and expertise of the Board of Directors and the Science and Technology Committee.
- Confirm whether the Board has initiated a search for a replacement director to fill the vacancy.
- Review subsequent filings for any financial updates, as this 8-K contains no financial data.